Hunter Smith Biography and Net Worth



Hunter Smith has been our Chief Financial Officer since August 2017, and served as our interim Chief Executive Officer from March to July 2020. Since joining Rhythm, Hunter led the company in an initial public offering that netted the Company $125 million, as well as two follow-on public offerings that netted approximately $346 million. As a member of the management team, Hunter has played a critical role in charting Rhythm’s corporate strategy and enabling its growth and development. He has over 25 years’ experience in global finance and management roles across multiple industries and financial disciplines, including expertise in business analysis and planning, mergers and acquisitions, capital raising and investor relations. He joined Rhythm from Celgene Corporation, where he served as Vice President, Finance and Chief Financial Officer of the Company’s Inflammation and Immunology Business Unit. In this role, Hunter provided finance leadership for the global launch of Otezla®, co-led the integration of Receptos, Inc. following its acquisition by Celgene, and led global business planning and analysis for operations in over 16 countries. Before joining Celgene, Hunter worked for fourteen years in roles of increasing responsibility at Bunge Limited, including Director of Investor Relations, Chief Financial Officer–Asia, Chief Risk Officer, Corporate Treasurer, and Chief Financial Officer of Bunge’s Sugar and Bioenergy Segment. He holds an MBA in Finance from NYU’s Stern School of Business and a BA in History, with honors, from Northwestern University. Hunter serves on the Board of Directors of Aeglea BioTherapeutics, Inc., and he previously served as an Independent Director of Genessee & Wyoming Inc. and as a member of the Compensation and Governance Committees, from 2015 until its acquisition by Brookfield Infrastructure Partners in December 2019.

What is Hunter C. Smith's net worth?

The estimated net worth of Hunter C. Smith is at least $5.47 million as of March 19th, 2024. Mr. Smith owns 97,939 shares of Rhythm Pharmaceuticals stock worth more than $5,469,893 as of December 24th. This net worth approximation does not reflect any other assets that Mr. Smith may own. Additionally, Mr. Smith receives an annual salary of $757,320.00 as CFO at Rhythm Pharmaceuticals. Learn More about Hunter C. Smith's net worth.

How old is Hunter C. Smith?

Mr. Smith is currently 55 years old. There are 6 older executives and no younger executives at Rhythm Pharmaceuticals. The oldest executive at Rhythm Pharmaceuticals is Dr. David P. Meeker M.D., Chairman, President & CEO, who is 70 years old. Learn More on Hunter C. Smith's age.

What is Hunter C. Smith's salary?

As the CFO of Rhythm Pharmaceuticals, Inc., Mr. Smith earns $757,320.00 per year. There are 2 executives that earn more than Mr. Smith. The highest earning executive at Rhythm Pharmaceuticals is Dr. David P. Meeker M.D., Chairman, President & CEO, who commands a salary of $1,350,000.00 per year. Learn More on Hunter C. Smith's salary.

How do I contact Hunter C. Smith?

The corporate mailing address for Mr. Smith and other Rhythm Pharmaceuticals executives is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. Rhythm Pharmaceuticals can also be reached via phone at (857) 264-4280 and via email at [email protected]. Learn More on Hunter C. Smith's contact information.

Has Hunter C. Smith been buying or selling shares of Rhythm Pharmaceuticals?

Hunter C. Smith has not been actively trading shares of Rhythm Pharmaceuticals over the course of the past ninety days. Most recently, Hunter C. Smith sold 15,515 shares of the business's stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $39.22, for a transaction totalling $608,498.30. Following the completion of the sale, the chief financial officer now directly owns 97,939 shares of the company's stock, valued at $3,841,167.58. Learn More on Hunter C. Smith's trading history.

Who are Rhythm Pharmaceuticals' active insiders?

Rhythm Pharmaceuticals' insider roster includes Pamela Cramer (Insider), Jennifer Good (Director), Jennifer Lee (EVP), Yann Mazabraud (EVP), David Meeker (CEO), Joseph Shulman (Insider), Hunter Smith (CFO), and Lynn Tetrault (Director). Learn More on Rhythm Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Rhythm Pharmaceuticals?

In the last twelve months, insiders at the sold shares 24 times. They sold a total of 392,931 shares worth more than $19,866,811.44. The most recent insider tranaction occured on November, 11th when EVP Jennifer Kayden Lee sold 66,861 shares worth more than $4,434,890.13. Insiders at Rhythm Pharmaceuticals own 5.6% of the company. Learn More about insider trades at Rhythm Pharmaceuticals.

Information on this page was last updated on 11/11/2024.

Hunter C. Smith Insider Trading History at Rhythm Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/19/2024Sell15,515$39.22$608,498.3097,939View SEC Filing Icon  
2/12/2024Sell1,209$51.38$62,118.4280,413View SEC Filing Icon  
12/5/2023Sell7,026$35.06$246,331.5661,406View SEC Filing Icon  
11/24/2023Sell10,974$35.02$384,309.4861,406View SEC Filing Icon  
2/14/2023Sell702$26.87$18,862.7459,406View SEC Filing Icon  
2/9/2023Sell1,398$27.66$38,668.6857,779View SEC Filing Icon  
7/1/2022Sell7,547$4.08$30,791.7657,614View SEC Filing Icon  
2/15/2022Sell833$6.10$5,081.30View SEC Filing Icon  
See Full Table

Hunter C. Smith Buying and Selling Activity at Rhythm Pharmaceuticals

This chart shows Hunter C Smith's buying and selling at Rhythm Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Rhythm Pharmaceuticals Company Overview

Rhythm Pharmaceuticals logo
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $55.85
Low: $55.34
High: $56.31

50 Day Range

MA: $56.51
Low: $47.73
High: $67.33

2 Week Range

Now: $55.85
Low: $35.17
High: $68.58

Volume

194,706 shs

Average Volume

548,630 shs

Market Capitalization

$3.43 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.14